Zoetis Inc.
Financials
Valuation Metrics
Zoetis Inc.'s Market Cap is $32.32B. At end of 2025 it was $54.90B. Ranked #443 of 3,111 in US market (top 14%), #314 of 1,666 on NYSE (top 19%), #23 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $32.32B | US#443/3,111 Sec#23/269 |
| Revenue | $9.51B | US#596/3,111 Sec#22/269 |
| Net Income | $2.64B | US#265/3,111 Sec#17/269 |
| Total Assets | $15.15B | US#749/3,111 Sec#24/269 |
| Net Assets | $3.23B | US#939/3,111 Sec#36/269 |
| Employees | 14,500 | US#475/3,111 Sec#12/269 |
| Value | ||
| P/E | 12.23x | US#432/3,111 Sec#20/269 |
| P/B | 10.00x | US#2,625/3,111 Sec#206/269 |
| P/S | 3.40x | US#1,925/3,111 Sec#53/269 |
| EV/EBITDA | 9.83x | US#743/3,111 Sec#28/269 |
| FCF Yield | 6.61% | US#970/3,111 Sec#39/269 |
| Profitability | ||
| ROE | 81.75% | US#50/3,111 Sec#7/269 |
| ROA | 17.44% | US#142/3,111 Sec#23/269 |
| Op. Margin | 37.57% | US#278/3,111 Sec#17/269 |
| Revenue Growth | 1.89% | US#2,063/3,111 Sec#121/269 |
| Earnings Growth | -4.75% | US#1,464/3,111 Sec#45/269 |
| Financial Health | ||
| Debt Ratio | 368.73% | US#2,255/3,111 Sec#226/269 |
| Total Debt | $9.24B | US#428/3,111 Sec#20/269 |
| FCF | $2.14B | US#329/3,111 Sec#18/269 |
| Cash | $1.94B | US#432/3,111 Sec#22/269 |
| Current Ratio | 3.15x | US#758/3,111 Sec#190/269 |
| Net Debt/EBITDA | 1.81x | US#1,293/3,111 Sec#57/269 |
| Dividend | ||
| Div. Yield | 2.75% | US#669/3,111 Sec#8/269 |
| Div. Growth | 15.85% | US#325/3,111 Sec#3/269 |
| Performance | ||
| 1Y Return | -47.29% | US#2,922/3,111 Sec#239/269 |
| 1M Return | 3.06% | US#737/3,111 Sec#44/269 |
| From 52W High | -51.59% | US#2,782/3,111 Sec#222/269 |
| 1Y MDD | -55.93% | US#2,614/3,111 Sec#204/269 |
| Trading | ||
| Volume | 4,251,480 shares | US#551/3,111 Sec#42/269 |
| Trading Value | $332M | US#416/3,111 Sec#22/269 |
| Per Share | ||
| EPS | $6.10 | US#524/3,111 Sec#18/269 |
| BPS | $7.60 | US#1,980/3,111 Sec#93/269 |
Company Info
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.